<DOC>
	<DOCNO>NCT01910090</DOCNO>
	<brief_summary>To assess bioequivalence Test oral formulation FLURBIPROFEN 100 mg FAMOTIDINE 20 mg MULTI-LAYER TABLET versus Reference ANTADYS®100 mg Comprimé Pelliculé &amp; PEPCID® ( Famotidine ) 20mg Tablets , USP .</brief_summary>
	<brief_title>Bioequivalence Study FLURBIPROFEN 100 mg FAMOTIDINE 20 mg MULTI-LAYER TABLET Healthy Subjects Under Fasting Conditions</brief_title>
	<detailed_description>An open-label , randomize , single dose , two-treatment , two-period , two-sequence , crossover bioequivalence washout period least 7 day dose Healthy mixed skin Arab &amp; Mediterranean Subjects age 18 45 year , body-mass index 18.5 30.0 kg/m2 inclusive , non-smokers light smoker ( smoker 10 cigarette per day ) .</detailed_description>
	<mesh_term>Famotidine</mesh_term>
	<mesh_term>Flurbiprofen</mesh_term>
	<criteria>1 . Healthy Male subject . 2 . Ethnic Group : Arab &amp; Mediterranean 3 . Race : Mixed skin ( white &amp; black skin people ) . 4 . Age 1845 year 5 . Bodymass index 18.5 30.0 kg/m2 inclusive 6 . Subject available whole study period give write informed consent 7 . Physical examination within normal range 8 . All laboratory screening result within normal range , assess clinically nonsignificant attend physician . 9 . Vital sign within normal range ( Unless clinical investigator classify insignificant ) . 10 . Normal Kidney &amp; Liver function test ( Unless clinical investigator classify insignificant ) . 11 . Normal Cardiovascular system . 12 . Normal Digestive system . 1 . Women . 2 . Ethnic Group ( Non Arab &amp; / Non Mediterranean ) 3 . History severe allergy allergic reaction study drug relate drug 4 . Known history presence food allergy , condition know interfere absorption , distribution , metabolism excretion drug 5 . History serious illness impact fate drug 6 . Known history presence cardiac , pulmonary , gastrointestinal , endocrine , musculoskeletal , neurological , hematological , liver kidney disease , unless judge clinically significant Principal Investigator , medical designate 7 . Clinically significant illness 4 week study Period I 8 . Mental disease , drug , alcohol , solvent caffeine abuse , smoke . 9 . Regular use medication 10 . Having take medication could affect investigated drug product : ) Regular consumption drug two week prior study initiation day , b ) consumption enzyme stimulate inhibit drug ( e.g . Barbiturates , Carbamazepine , Phenytoin ) one month study initiation . 11 . Presence significant physical organ abnormality 12 . Donation 1 ) least 400 ml blood within 60 day , 2 ) 150 ml blood within 30 day , 3 ) 100 ml blood plasma platelet within 14 day study Period I 13 . Participation another bioequivalence study within 80 day prior start study Period I 14 . Following special diet ( e.g . vegetarian ) diet one month study initiation . 15 . History Gastrointestinal diseases 16 . Prior history hypersensitivity Flurbiprofen Famotidine competitive inhibitor histamine H2receptors . 17 . Consumption grapefruit grapefruit containing product within 7 day drug administration 18 . Ingestion vitamins herbal product within 7 day prior initial dose study medication . 19 . Exhausting physical exercise last 48 hour ( e.g . weight lift ) recent significant change dietary exercise habit . 20 . Any significant clinical abnormality include HBsAg , HCV , HIV 21 . Abnormal vital sign 22 . Abnormal Kidney Liver function test . 23 . Abnormal Cardiovascular system . 24 . Abnormal Digestive system 25 . Vomiting , Diarrhea .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>fast condition</keyword>
</DOC>